Identifying triggers and risk factors for Reversible Cerebral Vasoconstriction Syndrome
Identification of Reversible Cerebral Vasoconstriction Syndrome's Precipitating Factors. Triggers And Risk Factors to Develop a Reversible Cerebral Vasoconstriction Syndrome
This study is trying to find out what triggers Reversible Cerebral Vasoconstriction Syndrome and what risk factors might affect how patients do over time.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 225 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University Hospital, Montpellier Academic / other |
| Locations | 1 site (Montpellier) |
| Trial ID | NCT04179383 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the potential precipitating and risk factors associated with Reversible Cerebral Vasoconstriction Syndrome (RCVS) through a prospective selection of well-characterized patients and controls. It will assess the impact of these factors on patient prognosis via follow-up evaluations. Additionally, the study will establish a clinicoradiological database and a biobank containing plasma, cerebrospinal fluid, and DNA for future multicenter research on RCVS. The study is designed as a monocentric analytic observational case-control study with interventional elements due to the collection of biological samples.
Who should consider this trial
Good fit: Ideal candidates include men and women aged 18 and older diagnosed with RCVS or suspected RCVS within 14 days prior to inclusion.
Not a fit: Patients with severe neurological conditions, coma, or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of RCVS, potentially improving patient outcomes.
How similar studies have performed: While this study explores a novel approach to understanding RCVS, similar studies have shown promise in identifying risk factors for other neurological conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * For the Patients * Men and women of 18 and more years old * Taken care in the CHU of Montpellier * Diagnosis of SVCR or SVCR without visible vasoconstriction makes in 14 days preceding the inclusion * According to the consensual criteria of diagnosis and those of the international classification of the headaches ICHD-3 * Informed consent and writes for the participation in the study * For volunteers * Men and women of 18 and more, mated in the Cases on the sex and the age * Patients with an acute pathology not Neurological and not vascular (for example, eye foreign body) OR Healthy Subjects * Informed written consent and for the participation in the study Exclusion criteria: * Coma, insanity, language barrier or severe aphasia preventing from answering the questions * Follow-up considered impossible for 3 months (e.g.: priority associated pathology in the care, the transfer(transformation)) * People placed under legal protection * Refusal to participate in the study
Where this trial is running
Montpellier
- Gui de Chauliac Hospital — Montpellier, France (Recruiting)
Study contacts
- Principal investigator: Lucas CORTI — CHU de Montpellier
- Study coordinator: Lucas CORTI
- Email: l-corti@chu-montpellier.fr
- Phone: 06.76.31.63.12
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.